Patents by Inventor Balazs Sarkadi

Balazs Sarkadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200284797
    Abstract: ABC multidrug transporters are key players in cancer multidrug resistance and in general xenobiotic elimination, thus their functional assays provide important tools for research and diagnostic applications. It has been found that in cells expressing functional ABCG2, ABCB1, or ABCC1 transporters, cellular PG fluorescence is strongly reduced. The invention relates to methods and uses of fluorescein derivative ester compounds of formula Ia which are analogs of PG for assessing ABC transporter activity of ABC multidrug transporters. The present accumulation assay is a novel tool for the parallel determination of the function of the multidrug transporters, in particular ABCG2, ABCB1, and ABCC1. The assay is applicable for diagnostic purposes and also allows the selection, separation and culturing of selected cell populations expressing such transporters.
    Type: Application
    Filed: October 25, 2018
    Publication date: September 10, 2020
    Inventors: Edit SZABÓ, Dóra KOVÁCS-TÜRK, Ágnes TELBISZ, Nóra KUCSMA, Tamás HORVÁTH, Gergely SZAKÁCS, László HOMOLYA, Balázs SARKADI, VÁRADY György
  • Patent number: 9465038
    Abstract: This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: October 11, 2016
    Assignee: AdvanCell Diagnosztika Kft.
    Inventors: Balázs Sarkadi, György Várady, Ildikó Kasza
  • Publication number: 20150111770
    Abstract: This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects.
    Type: Application
    Filed: April 22, 2013
    Publication date: April 23, 2015
    Applicant: AdvanCell Diagnosztika Kft.
    Inventors: Balázs Sarkadi, György Várady, Ildikó Kasza
  • Patent number: 8129197
    Abstract: The invention provides for a novel cholesterol loaded insect cell membrane preparation having an increased cholesterol level as compared to physiological cholesterol levels of insect cell membranes or to control insect cell membrane preparations without cholesterol loading, wherein said cholesterol loaded membrane preparation comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preparations of the invention. The invention also relates to methods for manufacturing said preparations and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compounds and interaction of compounds and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: March 6, 2012
    Assignee: SOLVO Biotechnológial ZRT.
    Inventors: György Báthori, Dóra Méhn, Pál Ákos, Péter Krajcsi, Lajos Szente, Éva Fenyvesi, Ágnes Telbisz, Balázs Sarkadi, András Váradi, Szilvia Gedey, Hristos Glavinas, Emese Kis, Tünde Nagy, Attila Németh, Éva Molnár
  • Publication number: 20100255505
    Abstract: Genetically modified stem cells and the selection of cells differentiated therefrom are disclosed. Particularly, the herein disclosed invention relates to stem cells or cells differentiated therefrom containing a copy of a stably inheritable expression construct that is suitable for the expression of transgenes in stem cells, wherein said construct comprises at least a double-feature constitutive promoter being operable both in stem cells and in differentiated tissues, the expression level thereof being subject to a tissue or cell type specific regulation in differentiated cells, and, optionally, under the control of said promoter, a transgene, wherein said transgene is expressed in the stem cell. Furthermore methods are disclosed to produce such stem cells, as well as specific uses of said stem cells in assay methods and in human therapy and in veterinary practice.
    Type: Application
    Filed: May 14, 2010
    Publication date: October 7, 2010
    Inventors: Agota Apáti, Zsuzsa Izsvák, Katalin Német, Tamás Orbán, Balázs Sarkadi
  • Publication number: 20100021927
    Abstract: The invention provides for a novel cholesterol loaded insect cell membrane preparation having an increased cholesterol level as compared to physiological cholesterol levels of insect cell membranes or to control insect cell membrane preparations without cholesterol loading, wherein said cholesterol loaded membrane preparation comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preparations of the invention. The invention also relates to methods for manufacturing said preparations and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compounds and interaction of compounds and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane.
    Type: Application
    Filed: May 14, 2007
    Publication date: January 28, 2010
    Inventors: György Báthori, Dóra Méhn, Pál Ákos, Péter Krajcsi, Lajos Szente, Éva Fenyvesi, Ágnes Telbisz, Balázs Sarkadi, András Váradi, Szilvia Gedey, Hristos Glavinas, Emese Kis, Tünde Nagy, Attila Németh, Éva Molnár
  • Publication number: 20080187935
    Abstract: The invention relates to methods for screening selective modulators of half transporter proteins of the ABCG family, more closely of ABCG1 and ABCG4. In particular the invention relates to methods for determining whether a substance is a selective activator, an inhibitor or a substrate of an ABCG1 or ABCG4 homodimer or of an ABCG1/ABCG4 heterodimer protein, methods for detection of ABCG1 protein in a biological sample, methods for modulating the function of said proteins, and methods for detecting the presence of and/or quantitating ABCG1/ABCG4 heterodimer activity in a biological sample. Moreover, the invention relates to isolated ABCG1/ABCG4 heterodimer proteins and antibodies selective for ABCG1 or ABCG4. The closely related human ABC half-transporters, ABCG1 and ABCG4, have been suggested to play an important role in cellular lipid/sterol regulation. ABCG1 and ABCG4 and mutants thereof have been expressed and studied by the present inventors in whole cells as well as isolated membrane preparations.
    Type: Application
    Filed: July 8, 2005
    Publication date: August 7, 2008
    Inventors: Judit Cserepes, N. Barry Elkind, Zsofia Szentpetery, Balazs Sarkadi, Andras Varadi, Izabella Klein, Laszlo Homolya, Laszlo Seres, Csilla Ozvegy-Laczka
  • Patent number: 7122329
    Abstract: The invention relates to a simple quantitative fluorescent assay method for determining the activity of transport proteins, more specifically multi-drug resistance associated proteins (MRPs). The method of the invention is performed on a well sealed culture of polarized cells expressing a transport protein of interest grown to confluency on a permeable support, said confluent cell culture forming well separated apical and basolateral compartments. The cells are contacted with a cell permeable non-fluorescent derivative of a fluorescent compound (e.g. calcein AM) in one compartment and, after a certain period of incubation, the fluorescence intensity detected in a sample taken from the opposite compartment is indicative of the activity of the transport protein of interest expressed in the cells.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: October 17, 2006
    Assignee: Solvo Biotechnology
    Inventors: László Homolya, Balázs Sarkadi, Raymond Evers
  • Publication number: 20050255084
    Abstract: The invention relates to an isolated nucleic acid comprising a sequence encoding a half transporter protein of the ABCG-family for use in gene therapy, to the use of the isolated nucleic acid for selecting somatic mammalian cells against at least one drug transportable by the transporter protein, to vectors, cells, pharmaceutical compositions and kits comprising the nucleic acid and methods for protecting and selecting cells against a cytotoxic drug transportable by said transporter protein and for gene therapy methods.
    Type: Application
    Filed: October 24, 2002
    Publication date: November 17, 2005
    Applicant: SOLVO BIOTECHNOLOGY
    Inventors: Katalin Nemet, Gyorgy Varady, Judit Cervenak, Olga Ujhelly, Balazs Sarkadi, Andras Varadi, Csilla Ozvegy
  • Publication number: 20040033508
    Abstract: The invention relates to a simple quantitative fluorescent assay method for determining the activity of transport proteins, more specifically multi-drug resistance associated proteins (MRPs). The method of the invention is performed on a well sealed culture of polarized cells expressing a transport protein of interest grown to confluency on a permeable support, said confluent cell culture forming well separated apical and basolateral compartments. The cells are contacted with a cell permeable non-fluorescent derivative of a fluorescent compound (e.g. calcein AM) in one compartment and, after a certain period of incubation, the fluorescence intensity detected in a sample taken from the opposite compartment is indicative of the activity of the transport protein of interest expressed in the cells.
    Type: Application
    Filed: July 24, 2003
    Publication date: February 19, 2004
    Inventors: Laszlo Homolya, Balazs Sarkadi, Raymond Evers
  • Publication number: 20030170730
    Abstract: The invention relates to a method for testing L0-specific inhibitors of transporter proteins of the MRP-family and for testing inhibitors specific to the predicted amphipatic helical region of the L0 region, the tested inhibitors L0 peptide, mutants thereof, polynucleotides coding the peptides. Vectors and hosts cells comprising the polynucleotides and reagent kits for testing and developing the inhibitors. The invention is especially useful for combatting multidrug resistance in cancer patients and in the field of related research.
    Type: Application
    Filed: May 2, 2003
    Publication date: September 11, 2003
    Inventors: Eva Bakos, Balazs Sarkadi, Andras Varadi, Gabor Tusnadi, Raymond Evers
  • Patent number: 6297216
    Abstract: The invention features novel peptide derivatives called Reversins, and provides for their use in a method of reducing the activity of the multi-drug transporter protein MDR1 in order to overcome multidrug resistance in a mammal. The peptide derivatives are of the formula (I) X1n-X2-X3(X4)n-X5, wherein n is 0 or 1, and each n is the same or different; X1 is BOC, BOC-Asu, Z-Asu, benzyloxycarbonyl, Glu(OBzl)-OBzl, Trp-OMe, Trp-Phe-OMe, Phe-Trp-OMe, Phe-Phe-OtBu, Trp-Trp-OtBu, indoloacetyl, benzoyl, an alkylanine of 1-4 carbons, dibenzylamide, tryptamide, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide or dicyclohexylamide; X2 is Glu(OBzl), Asp(OBzl), succinyl, O,O-dibenzoyltartaroyl, diphenoyl, muconyl, Thx, Cpa, Asu, Nal, Pen, Phg, Dbt, Lys(BOC), Lys(Z), Cys(Bzl), Thr(Bzl), Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Phe, Tyr(Bzl), or Ser(Bal); X3 is Asp, Asu, Lys, Glu, Trp, Thx, Cpa, Nal, Pen, Phg, Dbt, Glu(OtBu), tert.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: October 2, 2001
    Assignee: Solvo Biotechnology
    Inventors: Balazs Sarkadi, Janos Seprodi, Orsolya Csuka, Maria Magocsi, Imre Mezo, Istvan Palyi, Istvan Teplan, Zsolt Vadasz, Borbala Vincze
  • Patent number: 6277655
    Abstract: Disclosed herein are methods and reagents kits forth quantitative in vitro determination of the functional determination of multi-drug resistance in cells, as well as for the clinical screening of potential modulators of multi-drug resistant transport activity in cells. The method of the invention is based on the measurement of the accumulation rate of free calcein within the cells of the specimen (advantageously by flourescence measurement), after exposing the cells in vitro to a cell permeable form of calcein that is a good substrate for MDR proteins present in the sample. The cell permeable form of calcein is converted within the cell by intracellular enzymes to free calcein. Comparison of free calcein accumulation in the presence and absence of a potential inhibitor of transport activity permits the rapid screening of such inhibitors.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: August 21, 2001
    Assignee: Solvo Biotechnology
    Inventors: Balázs Sarkadi, László Homolya, Zsolt Holló
  • Patent number: 5872014
    Abstract: The invention generally features a rapid, quantitative method of diagnosing multi-drug resistance in a patient. The method involves (a) exposing cells of a biological specimen to a calcein compound, the calcein compound becoming fluorescent in the cell; and (b) measuring calcein compound accumulating in the specimen cells relative to control cells, reduced calcein accumulation in specimen cells relative to control cells indicating the presence of multi-drug resistance in the biological specimen. The method is useful for diagnosing multi-drug resistance in patients undergoing drug therapy, e.g., chemotherapeutic or antibiotic therapy.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: February 16, 1999
    Inventors: Balazs Sarkadi, Laszlo Homolya, Zsolt Hollo